End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study

2018 ◽  
Vol 48 (9) ◽  
pp. 1123-1132
Author(s):  
Hsin-Fu Lee ◽  
Lai-Chu See ◽  
Yi-Hsin Chan ◽  
Yung-Hsin Yeh ◽  
Lung-Sheng Wu ◽  
...  
Keyword(s):  
End Stage Renal Disease ◽  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Risk Of Mortality ◽  
Receptor Blockers ◽  
Stage Renal Disease ◽  
End Stage

Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes

2013 ◽  
Vol 102 (3) ◽  
pp. 233-241 ◽  
Author(s):  
Heather M. Campbell ◽  
Nasreen Khan ◽  
Dennis W. Raisch ◽  
Matthew E. Borrego ◽  
Mike R. Sather ◽  
...  
Keyword(s):  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Disease Mortality ◽  
Receptor Blockers ◽  
Stage Renal Disease ◽  
End Stage

Abstract 12830: Primary Prevention of Atrial Fibrillation With Angiontensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients of End-Stage Renal Disease- A Nationwide Cohort Study Using Insurance Claims Database

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Ting-Tse Lin ◽  
Min-Tsun Liao ◽  
Lian-Yu Lin
Keyword(s):  
Primary Prevention ◽  
End Stage Renal Disease ◽  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers ◽  
Stage Renal Disease ◽  
End Stage

Background: Current evidence suggests that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARB) reduce the incidence of new atrial fibrillation (AF) in a variety of settings including the treatment of left ventricular dysfunction or hypertension. This study was to assess whether ACEIs and ARB could decrease incidence of AF in patients of end stage renal disease (ESRD). Materials and Methods: We identified all patients who developed ESRD through January 1998 to December 2008 from the National Health Insurance Research Database, Taiwan. The primary endpoint was new onset of AF and the median duration of follow up was 1499 days. The control group was patients not prescribing ACEIs or ARB. Hazard ration of both ACEIs vs. control and ARB vs. control were analyzed. Results: Among 102688 patients, 14926 (14.5%) were prescribed with ACEIs, 16282 (15.9) with ARB but 71480 (69.6%) were not prescribed ACEIs or ARB. Overall, patients treated with ACEIs (adjusted hazard ratio [HR] 0.587, 95% confidence interval [CI] 0.519-0.633, P<0.001 ) or ARB (adjusted HR 0.542, 95% CI 0.461-0.637, P<0.001 ) had a reduced incidence of AF. The preventive effect between two classes of drugs was favored ARB (P<0.001). The longer patients taking ACEIs or ARB, the better prevention of AF are. The similar reduction of AF is also noted in stratified analysis of age, gender, hypertension, congestive heart failure and diabetes. Conclusion: Both ACEIs and ARB appear to be effective in the primary prevention of AF in ESRD patients. This analysis supports the concept of renin-angiotensin system inhibition as an emerging treatment for the primary prevention of AF.

scholarly journals Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study

2018 ◽  
Vol 34 (7) ◽  
pp. 1216-1222 ◽  
Author(s):  
João Pedro Ferreira ◽  
Cécile Couchoud ◽  
John Gregson ◽  
Aurélien Tiple ◽  
François Glowacki ◽  
...  
Keyword(s):  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers ◽  
Β Blockers ◽  
Cv Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Abstract Background End-stage renal disease (ESRD) patients even without known cardiovascular (CV) disease have high mortality rates. Whether neurohormonal blockade treatments improve outcomes in this population remains unknown. The aim of this study was to assess the effect of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), β-blockers or both in all-cause mortality rates in incident ESRD patients without known CV disease starting renal replacement therapy (RRT) between 2009 and 2015 in the nationwide Réseau Epidémiologie et Information en Néphrologie registry. Methods Patients with known CV disease and those who started emergency RRT, stopped RRT or died within 6 months were excluded. Propensity score matching models were used. The main outcome was all-cause mortality. Results A total of 13 741 patients were included in this analysis. The median follow-up time was 24 months. When compared with matched controls without antihypertensive treatment, treatment with ACEi/ARBs, β-blockers and ACEi/ARBs + β-blockers was associated with an event-rate reduction per 100 person-years: ACEi/ARBs 7.6 [95% confidence interval (CI) 7.1–8.2] versus matched controls 9.5 (8.8–10.1) [HR 0.76 (95% CI 0.69–0.84)], β-blocker 7.1 (6.6–7.7) versus matched controls 9.5 (8.5–10.2) [HR 0.72 (0.65–0.80)] and ACEi/ARBs + β-blockers 5.8 (5.4–6.4) versus matched controls 7.8 (7.2–8.4) [HR 0.68 (0.61–0.77)]. Conclusions Neurohormonal blocking therapies were associated with death rate reduction in incident ESRD without CV disease. Whether these relationships are causal will require randomized controlled trials.

Diabetic Nephropathy

2011 ◽  
Vol 4 (12) ◽  
pp. 706-711 ◽  
Author(s):  
Rafay Iqbal ◽  
Shahzad Hussain Shah
Keyword(s):  
Diabetic Nephropathy ◽  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme Inhibitors ◽  
Multiple Risk Factors ◽  
History Of ◽  
Receptor Blockers ◽  
Stage Renal Disease ◽  
End Stage

Diabetic nephropathy is the leading cause of renal failure in UK, accounting for 24% of patients with end-stage renal disease (ESRD). In addition, it is a risk factor for cardiovascular disease. Clinical trials have shown that it is possible to alter the natural history of diabetic nephropathy by targeting multiple risk factors. In clinical practice, this includes tight glycaemic control, aggressive antihypertensive therapy and the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). This article aims to describe management of diabetic nephropathy in primary care and provide guidance on when to refer to secondary care.

Sign in / Sign up

Export Citation Format

Share Document